肥胖相关心力衰竭作为盐皮质激素受体拮抗剂治疗的理论靶点
本文综述了腹部肥胖与醛固酮水平及盐皮质激素受体拮抗剂疗效的关联。分析显示,在射血分数降低的心衰试验中,腹型肥胖患者主要终点风险降低约50%,获益幅度是腰围正常者的两倍以上且耐受性更好;在射血分数保留的心衰试验中,利钠肽水平提示腹型肥胖可能性高的患者使用螺内酯主要终点风险降低约80%(基于少量事件)。结论认为腹型肥胖可能识别最可能从盐皮质激素受体拮抗剂获益的患者,测量腰围有助于推动该类药物的临床应用。
要点
- 腹型肥胖与循环醛固酮水平强相关,可能识别盐皮质激素受体拮抗剂获益人群。
- HFrEF试验中腹型肥胖患者主要终点风险降低约50%,获益幅度是腰围正常者的两倍以上。
- HFpEF试验中利钠肽提示腹型肥胖可能性高的患者使用螺内酯主要终点风险降低约80%。
核心结论
- 腹型肥胖可能识别对盐皮质激素受体拮抗剂反应最有利的慢性心衰患者。
- 测量腰围简单易行,靶向腰围增加的患者可促进该类药物的临床采用。
研究设计与样本
- 本文为基于两项心衰试验的事后分析进行的综述性观察。
- 一项为射血分数降低的心衰试验,另一项为射血分数保留的心衰试验。
主要发现
- 腹部肥胖与循环醛固酮水平强相关,腹型肥胖标志物可识别最可能从盐皮质激素受体拮抗剂获益的患者。
- 在射血分数降低的心衰试验中,腰围增加的患者主要终点风险降低约50%。
- 腹型肥胖患者的获益幅度是腰围正常者的两倍以上,且腹型肥胖患者对治疗耐受性更好。
- 在射血分数保留的心衰试验中,利钠肽水平提示腹型肥胖可能性最高的患者使用螺内酯主要终点风险降低约80%(基于少量事件)。
关键数值与推荐
- 射血分数降低的心衰试验:腰围增加患者主要终点风险降低约50%。
- 射血分数降低的心衰试验:腹型肥胖患者获益幅度是腰围正常者的两倍以上。
- 射血分数保留的心衰试验:利钠肽提示腹型肥胖可能性高的患者使用螺内酯主要终点风险降低约80%(基于少量事件)。
临床怎么用
- 对慢性心衰患者测量腰围,可识别可能从盐皮质激素受体拮抗剂获益的腹型肥胖患者。
- 腹型肥胖患者对盐皮质激素受体拮抗剂耐受性更好,可考虑优先选用。
局限性
- 上述分析均为事后分析,并非预设的主要分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite their clinical benefits, mineralocorticoid receptor antagonists are greatly underprescribed by most practitioners who treat patients with chronic heart failure. A novel approach to encouraging the use of these drugs is to enhance awareness about the intimate link between aldosterone and obesity. OBSERVATIONS: There is a strong association between abdominal obesity and circulating levels of aldosterone, and markers of abdominal obesity identify patients most likely to benefit from mineralocorticoid receptor antagonism. In a trial of patients with heart failure and a reduced ejection fraction, patients with an increased waist circumference exhibited an approximately 50% reduction in the risk of a primary end point. The magnitude of benefit was more than twice as great in patients with abdominal obesity than in those with a normal waist circumference, and patients with abdominal obesity tolerated treatment better than nonobese patients. Similarly, in a trial of patients with heart failure and a preserved ejection fraction, those who were most likely to have abdominal obesity (identified by their level of natriuretic peptides) were most likely to demonstrate a benefit of treatment with spironolactone, exhibiting an approximately 80% reduction in the risk of a primary end point (based on a small number of events). CONCLUSIONS AND RELEVANCE: Although these analyses are post hoc, their concordance and strong biological foundation suggests that abdominal obesity may identify patients who respond most favorably to mineralocorticoid receptor antagonism. Given the easy availability of its measurement, targeting patients with an increased waist circumference could enhance the adoption of these important drugs for the treatment of chronic heart failure in clinical practice.
引用
- Packer M. Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. JAMA Cardiol. 2018. PMID: 30046826. doi:10.1001/jamacardio.2018.2090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。